These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10225128)

  • 1. Methodological and clinical challenges in evaluating treatment outcome of substance-related disorders and comorbidity.
    el-Guebaly N; Hodgins DC; Armstrong S; Addington J
    Can J Psychiatry; 1999 Apr; 44(3):264-70. PubMed ID: 10225128
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An integrated treatment program for dually diagnosed patients.
    Bachmann KM; Moggi F; Hirsbrunner HP; Donati R; Brodbeck J
    Psychiatr Serv; 1997 Mar; 48(3):314-6. PubMed ID: 9057232
    [No Abstract]   [Full Text] [Related]  

  • 3. Increasing program capability to provide treatment for co-occurring substance use and mental disorders: organizational characteristics.
    Gotham HJ; Claus RE; Selig K; Homer AL
    J Subst Abuse Treat; 2010 Mar; 38(2):160-9. PubMed ID: 19717273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of outpatient intensive treatment for drug abuse.
    Campbell J; Gabrielli W; Laster LJ; Liskow BI
    J Addict Dis; 1997; 16(2):15-25. PubMed ID: 9083822
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders.
    Barrowclough C; Haddock G; Tarrier N; Lewis SW; Moring J; O'Brien R; Schofield N; McGovern J
    Am J Psychiatry; 2001 Oct; 158(10):1706-13. PubMed ID: 11579006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GPRA and the development of performance measures.
    Darby K; Kinnevy SC
    J Evid Based Soc Work; 2010 Jan; 7(1):5-14. PubMed ID: 20178021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gender differences in treatment retention among individuals with co-occurring substance abuse and mental health disorders.
    Choi S; Adams SM; Morse SA; MacMaster S
    Subst Use Misuse; 2015 Apr; 50(5):653-63. PubMed ID: 25587672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Follow-up contact bias in evaluation of substance abuse treatment programs.
    Rohrer JE; Vaughan MS; Cadoret R; Zwick J
    Adm Policy Ment Health; 1999 Jan; 26(3):207-12. PubMed ID: 10339835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized clinical trial of a new behavioral treatment for drug abuse in people with severe and persistent mental illness.
    Bellack AS; Bennett ME; Gearon JS; Brown CH; Yang Y
    Arch Gen Psychiatry; 2006 Apr; 63(4):426-32. PubMed ID: 16585472
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating the effectiveness of addiction treatments: reasonable expectations, appropriate comparisons.
    McLellan AT; Woody GE; Metzger D; McKay J; Durrell J; Alterman AI; O'Brien CP
    Milbank Q; 1996; 74(1):51-85. PubMed ID: 8596524
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dual Diagnosis Capability of Residential Addiction Treatment centres: priorities and confidence to improve capability following a review process.
    Matthews H; Kelly PJ; Deane FP
    Drug Alcohol Rev; 2011 Mar; 30(2):195-9. PubMed ID: 21355921
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guidelines for using standardized outcome measures following addictions treatment.
    Graham K
    Eval Health Prof; 1994 Mar; 17(1):43-59. PubMed ID: 10171802
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual diagnosis demonstration project: treatment outcomes and cost analysis.
    Judd PH; Thomas N; Schwartz T; Outcalt A; Hough R
    J Psychoactive Drugs; 2003 May; 35 Suppl 1():181-92. PubMed ID: 12825761
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluating and improving VA substance abuse patients' care.
    Moos RH; Humphreys K; Ouimette PC; Finney J
    Am J Med Qual; 1999; 14(1):45-54. PubMed ID: 10446663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mental health indicator interaction in predicting substance abuse treatment outcomes in nevada.
    Greenfield L; Wolf-Branigin M
    Am J Drug Alcohol Abuse; 2009; 35(5):350-7. PubMed ID: 20180663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Severe mental illness and addictions: assessment considerations.
    Carey KB; Correia CJ
    Addict Behav; 1998; 23(6):735-48. PubMed ID: 9801713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Substance abuse relapse in a ten-year prospective follow-up of clients with mental and substance use disorders.
    Xie H; McHugo GJ; Fox MB; Drake RE
    Psychiatr Serv; 2005 Oct; 56(10):1282-7. PubMed ID: 16215196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association between substance use and the needs of patients with psychiatric disorder, levels of anxiety, and caregiving burden.
    Cleary M; Hunt GE; Matheson S; Walter G
    Arch Psychiatr Nurs; 2008 Dec; 22(6):375-85. PubMed ID: 19026926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment career snapshots: profiles of first treatment and previous treatment clients.
    Claus RE; Mannen RK; Schicht WW
    Addict Behav; 1999; 24(4):471-9. PubMed ID: 10466843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of treatment elements in a residential-work therapy program for veterans with severe substance abuse.
    Rosenheck R; Seibyl CL
    Psychiatr Serv; 1997 Jul; 48(7):928-35. PubMed ID: 9219302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.